Virtual Event

The Spatial Biology Week™ 2022

Your front-row seat to world innovators.

Register Now

OCTOBER 03-07

FREE REGISTRATION

ONLINE

Event agenda

Spatial biology is happening now. From the way hypothesis are generated and multi-omics data are collected to advance drug discovery and develop targeted treatment, the new spatial paradigm has opened up new avenues and angles for accelerating scientific research.

The Spatial Biology Week™ represents a unique opportunity for the scientific community to connect with and learn from world-class experts. This 5-day virtual meeting will bring you unique insights into spatial approaches and the latest innovations in multi-omics spatial discovery to answer novel biological questions.

Join live talks, roundtables, and Q&As to discuss the latest advancements in utilizing spatial data in biology and overcoming technical challenges. Registration is free, check the full event agenda below.

The Spatial Biology Week™ speakers list includes:

  • Jared K. Burks, Ph.D. – The University of Texas MD Anderson Cancer Center (USA)
  • Carlo Bifulco, MD – Providence, Earle A. Chiles Research Institute (USA)
  • Joe Yeong, MBBS, Ph.D. – IMCB, A*STAR, Singapore General Hospital (Singapore)
  • Denis Schapiro, Ph.D. – Heidelberg University Hospital (Germany)
  • Michael Surace, Ph.D. – AstraZenenca (USA)
  • Ghislaine Lioux, Ph.D. –  Indica Labs (USA)
  • Kelly Hunter, MsC – ProPath (UK)
  • Charlotte Stadler, Ph.D. – SciLifeLab (Sweden)
  • Alexander Klimowicz, Ph.D. – Boehringer Ingelheim (USA)
  • Matthew Pugh, MD Ph.D. – University of Birmingham (UK)
  • David Mason, Ph.D. – Visiopharm (DNK)

Access the full agenda below.

DISCLAIMER: Participation in the event is the sole decision of the speakers. The presentations are based on their personal experience and do not imply any official endorsement by their institutions.

Is registration mandatory to access the talks?
Yes. To attend the virtual event, you must be registered. Upon registration, you will receive via email a unique link to access the live talks.
Registration takes just 2 minutes.

How much is the registration?
Registration to the event is free.

Can I ask questions to the speakers?
Yes, all the presentations indicated in the agenda include a 5-min live Q&A

Will the talks be available on-demand?
Yes, the majority of the talks will be accessible on-demand after the event.

I would need support to complete my registration/access the talks
To receive support, please email [email protected]

I have a question regarding the event
Please send your request to [email protected]

October 3rd

Spatial Biology: the new dimension to breakthrough research

October 3rd

2:45 PM CEST | 8:45 AM EDT

Speaker

Diego Dupouy, PhD

Diego Dupouy, PhD

Chief Technology Officer & Founder

Lunaphore Technologies

Dr. Diego Dupouy studied bioengineering in Argentina. In 2008, he was awarded a scholarship to pursue a Master’s degree in Nanotechnologies, as a joint program between Politecnico di Torino (Italy), INPG (France), and EPFL. He led his master’s project at IBM Research (California). He pursued a PhD from EPFL, dealing with the development of microfluidic systems for applications in the field of tissue-based diagnostics. Diego is one of the founders and CTO of Lunaphore. He is in charge of leading the activities of the R&D and Scientific Affairs teams, including the development of our instruments, microfluidic chips, immunohistochemical assays, software, and scientific partnerships.

October 3rd

3:00 PM CEST | 9:00 AM EDT

Speaker

Denis Schapiro, PhD

Denis Schapiro, PhD

Group Leader

University Hospital Heidelberg

Since May 2021, Dr. Denis Schapiro is a Research Group Leader at the Heidelberg University Hospital focusing on spatial omics technologies and analysis.

Before moving to Heidelberg, he was an Independent Fellow at the Laboratory of Systems Pharmacology at Harvard Medical School and the Klarman Cell Observatory at the Broad Institute where he was a a Damon Runyon Quantitative Biology Fellow mentored by Prof. Peter Sorger and Prof. Aviv Regev. Previously, he was supported by the SNFS Mobility Fellowship.

Denis obtained his PhD from the University of Zurich and ETH Zurich in the laboratory of Prof. Bernd Bodenmiller where he worked on Imaging Mass Cytometry and corresponding analysis tools focusing on highly multiplexed image analysis. Denis is the lead developer of the histology topography cytometry analysis toolbox (histoCAT) and the multiple choice microscopy pipeline (MCMICRO).

Prior to this, he received his diploma (Dipl. Biol. (t.o)) at the University of Stuttgart and Harvard Medical School working with Prof. Peter Sorger and Prof. Alfred Goldberg. He was also an intern at the Complex Systems Modeling Group at Bayer AG in Leverkusen focusing on PBPK modeling.

October 3rd

3:30 PM CEST | 9:30 AM EDT

Multiple clinical trials have shown an overall improved response rate in cancers by combining radiotherapy (RT) with immunotherapy (IO), however, treatment rates remain low and unpredictable. The suboptimal outcomes are largely due to the lack of knowledge of the underlying immunomodulation effect and an effective treatment-response biomarker. Previous studies using tissue-based assays like multiplexed immunofluorescence (mIF) have demonstrated that cellular spatial organization within the tumor microenvironment represents a critical factor influencing anti-tumor immunity. Hence, we sought to characterize the in-situ molecular immune response of RT-treated cancer tissues by using multiple spatial and immunology technologies, to advance our understanding of RT-induced immunomodulation effect and its synergistic benefits with IO.

Speaker

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Group Leader

Institute of Molecular and Cell Biology, A*STAR, Singapore | Department of Anatomical Pathology, Singapore General Hospital

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also a board member of Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre.

October 3rd

4:00 PM CEST | 10:00 AM EDT

Speaker

Carlo Bifulco, MD

Carlo Bifulco, MD

Member and Director, Translational Molecular Pathology and Molecular Genomics

Earle A. Chiles Research Institute, Providence

Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco currently serves as Chief Medical Officer, Providence Genomics, and as Member and Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute. He oversees Providence Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven-state PSJH system.

Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at Yale University and completed fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center. His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics with immunotherapies. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC), and is Co-Chair of the SITC Pathology Task Force convened to establish multiplexed immunohistochemistry/ immunofluorescence (mIHC/IF) standards.

October 3rd

4:30 PM CEST | 10:30 AM EDT

Dissertation points:

  • Desired features of spatial biology technologies
  • Relationship between tissue biomarkers and liquid biopsies in oncology
  • The next in the quest to understand cancer tissue microenvironment dynamics

Speakers

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Group Leader

Institute of Molecular and Cell Biology, A*STAR, Singapore | Department of Anatomical Pathology, Singapore General Hospital

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also a board member of Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre.

Carlo Bifulco, MD

Carlo Bifulco, MD

Member and Director, Translational Molecular Pathology and Molecular Genomics

Earle A. Chiles Research Institute, Providence

Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco currently serves as Chief Medical Officer, Providence Genomics, and as Member and Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute. He oversees Providence Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven-state PSJH system.

Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at Yale University and completed fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center. His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics with immunotherapies. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC), and is Co-Chair of the SITC Pathology Task Force convened to establish multiplexed immunohistochemistry/ immunofluorescence (mIHC/IF) standards.

October 4th

From bench to bedside: spatial biology to advance clinical research

October 4th

3:00 PM CEST | 9:00 AM EDT

  • In the context of biomarker discovery, what are the common challenges around the analysis of tissue 
  • How can spatial proteomics be used to overcome these
  • What approaches does Propath UK use to streamline multiplexed IF/IHC 
  • Designing biomarker discovery projects using spatial technologies

Speaker

Kelly Hunter, MSc

Kelly Hunter, MSc

Chief Scientific Officer

ProPath UK

October 4th

3:30 PM CEST | 9:30 AM EDT

Speakers

Alexander Klimowicz, PhD

Alexander Klimowicz, PhD

Principal Scientist - Immunology and Respiratory Discovery Research

Boehringer Ingelheim

Dr. Alex Klimowicz is a Principal Scientist in the Department of Immunology and Respiratory Discovery Research at Boehringer Ingelheim Pharmaceuticals, Inc. In this capacity he leads the Molecular Histopathology Group, implementing and applying cutting edge in situ techniques, whole slide imaging, and digital image analysis, to build target to disease linkage in human tissue specimens for projects and external collaborations across the Department. Alex holds a PhD in Molecular Biology, and has 10 years of experience in the fields of digital pathology and quantitative immunohistochemistry. Prior to moving to Boehringer Ingelheim, Alex was an Adjunct Research Assistant Professor in the Department of Oncology at the University of Calgary, where he led a core quantitative immunohistochemistry lab focused on cancer biomarker research.

Priyank Patel, PhD

Priyank Patel, PhD

Senior Scientist

Boehringer Ingelheim

October 4th

4:00 PM CEST | 10:00 EDT

Multiplex immunofluorescence platforms capable of staining 40+ markers on a single 4 mm tissue are an incredible tool for interrogating the pathology of a variety of disease processes, in particular immune responses to cancers. While these platforms are capable of providing deep and high-resolution multimarker and spatial data from a single sample, there are specific risks to guard against. These include artifacts related to sensitivity, dynamic range, spectral bleed, and signal carryover from staining cycles. Of course, any significant observation made in multiplex IF must be corroborated using orthogonal measures, but due to the expense and effort required to perform the experiments, the potential impact of the results, and the precious nature of the samples, a properly validated assay is required. There is currently no standard validation approach for multiplex IF. Here we review our first experience with a beta unit of the Lunaphore COMET, inclusive of operation, performance, panel development, as well as a prototype validation

  • COMET technology walkthrough + mIF landscape
  • What a multiplex validation should cover
  • Comet validation plan
  • What worked & lessons learned

Speaker

Michael Surace, PhD

Michael Surace, PhD

Associate Director

AstraZeneca

Michael Surace received a BS in Biology from James Madison University in 2004 before joining the Medical Automation Research Center in the Department of Pathology at the University of Virginia. In 2006 he began graduate studies in the laboratory of Dr. Liwu Li, working on nuclear receptor and TLR signaling network crosstalk and its role in the polarization of macrophage activation phenotypes (M1/M2). He received his Ph.D. from Virginia Tech in 2010. Postdocs were at the Medical College of Virginia at Virginia Commonwealth University in Richmond, Virginia, in the departments of Anatomy and Neurobiology, investigating the cellular mechanisms of microglial activation in response to toxic insult in Parkinson’s Disease and Molecular Biology and Biochemistry, working on astrocytes as inflammatory immune cells in multiple sclerosis. In 2015 he joined STCube Pharmaceuticals as a research scientist characterizing novel immune checkpoint inhibitor antibodies with multiplex immunofluorescence and digital pathology image analysis to support mechanistic action research. In 2017 he joined Medimmune/ AstraZeneca as a scientist developing and validating Multiplex IF panels. Since then, he has continued developing the mIF platform inside Translational Medicine Oncology, focusing on validation of panels, reproducibility across sites, and improving the image and data analysis pipelines for research and clinical trials to support the development of predictive and prognostic models incorporating multiple markers and spatial information.

October 4th

4:30 PM CEST | 10:30 AM EDT

Discussion points: 

  • Multiplex panel validation: challenges and opportunities
  • Ideal technological requirements in a biopharma setting
  • Spatially-resolved biomarkers use in a clinical setting

Speakers

Alexander Klimowicz, PhD

Alexander Klimowicz, PhD

Principal Scientist - Immunology and Respiratory Discovery Research

Boehringer Ingelheim

Dr. Alex Klimowicz is a Principal Scientist in the Department of Immunology and Respiratory Discovery Research at Boehringer Ingelheim Pharmaceuticals, Inc. In this capacity he leads the Molecular Histopathology Group, implementing and applying cutting edge in situ techniques, whole slide imaging, and digital image analysis, to build target to disease linkage in human tissue specimens for projects and external collaborations across the Department. Alex holds a PhD in Molecular Biology, and has 10 years of experience in the fields of digital pathology and quantitative immunohistochemistry. Prior to moving to Boehringer Ingelheim, Alex was an Adjunct Research Assistant Professor in the Department of Oncology at the University of Calgary, where he led a core quantitative immunohistochemistry lab focused on cancer biomarker research.

Michael Surace, PhD

Michael Surace, PhD

Associate Director

AstraZeneca

Michael Surace received a BS in Biology from James Madison University in 2004 before joining the Medical Automation Research Center in the Department of Pathology at the University of Virginia. In 2006 he began graduate studies in the laboratory of Dr. Liwu Li, working on nuclear receptor and TLR signaling network crosstalk and its role in the polarization of macrophage activation phenotypes (M1/M2). He received his Ph.D. from Virginia Tech in 2010. Postdocs were at the Medical College of Virginia at Virginia Commonwealth University in Richmond, Virginia, in the departments of Anatomy and Neurobiology, investigating the cellular mechanisms of microglial activation in response to toxic insult in Parkinson’s Disease and Molecular Biology and Biochemistry, working on astrocytes as inflammatory immune cells in multiple sclerosis. In 2015 he joined STCube Pharmaceuticals as a research scientist characterizing novel immune checkpoint inhibitor antibodies with multiplex immunofluorescence and digital pathology image analysis to support mechanistic action research. In 2017 he joined Medimmune/ AstraZeneca as a scientist developing and validating Multiplex IF panels. Since then, he has continued developing the mIF platform inside Translational Medicine Oncology, focusing on validation of panels, reproducibility across sites, and improving the image and data analysis pipelines for research and clinical trials to support the development of predictive and prognostic models incorporating multiple markers and spatial information.

Kelly Hunter, MSc

Kelly Hunter, MSc

Chief Scientific Officer

ProPath UK

October 5th

Spatial Biology beyond immuno-oncology - Flexibility to scale up discoveries

October 5th

3:00 PM CEST | 9:00 AM EDT

  • The added value of in situ spatial proteomics
  • The next era of pathology – from single plex to broad panels
  • How can you access the latest spatial omics technologies for your research

Speaker

Charlotte Stadler, PhD

Charlotte Stadler, PhD

Co-Director Spatial and Single Cell Biology Platform, Head of Spatial Proteomics

SciLifeLab

Charlotte Stadler is a co-director of the Spatial and single cell Biology (SSCB) platform at Science for Life Laboratory. She is also the Head of the National Spatial Proteomics facility. She received her Ph.D. in 2012 within the framework of the Human Protein Atlas (HPA) project, with Prof. Emma Lundberg and Prof. Mathias Uhlén as her supervisors. During her PhD she established many of the protocols and pipelines for image based subcellular protein profiling that are used in the Human Protein Cell Atlas.

Today, her main focus is to develop and implement services and technologies that can be offered by the Spatial Proteomics Facility. Her internal research projects focus on the implementation of multiplexed imaging solutions into clinical practice but also on integrating different omics types for a more complete molecular understanding of the tissue sample biology.

For more information:

https://www.scilifelab.se/facilities/cell-profiling/

https://www.proteinatlas.org/

October 5th

3:30 PM CEST | 9:30 AM EDT

The SARS-CoV-2 virus is not only associated with respiratory tract infection, but can also infect other organs such as the placenta, resulting in unique clinical syndromes depending on the organ infected. Through the use of multiomic spatial profiling of SARS-CoV-2 infected tissue, including lung and placenta, we demonstrate that:

  • Detection of virus in tissue requires a robust muitiomic approach
  • SARS-CoV-2 infection elicits a unique inflammatory response
  • Virus infection in lung is associated with dysregulated collagen synthesis
  • Placental infection is typified by competing anti-viral and immune evasive responses.

Speaker

Matthew Pugh, MD PhD

Matthew Pugh, MD PhD

MRC Clinical Research Training Fellow

University of Birmingham

October 5th

4:00 PM CEST | 10:00 AM EDT

Discussion points:

  • Pros and Cons of an open technology platform for spatial biology
  • Spatial protein versus RNA biomarkers
  • Most promising fields outside oncology where spatial biology can make a long-lasting impact

Speakers

Jared K Burks, PhD

Jared K Burks, PhD

Professor & Co-Director of the Flow Cytometry & Cellular Imaging Core Facility

The University of Texas MD Anderson Cancer Center  

I started my carrier at Texas A&M University learning about patterns in genes and proteins, allowing and facilitating subcellular protein trafficking.  As I have progressed to MD Anderson Cancer Center, I have scaled to cellular trafficking attempting to understand the spatial distribution of cells in organ systems during disease.  As in many parts of life, form equals functions.  How our cells organize speaks to how they function and respond to their local environment.  Bringing together multi-omics approaches allows for greater clarity in these imaging snapshots that are collected.

Charlotte Stadler, PhD

Charlotte Stadler, PhD

Co-Director Spatial and Single Cell Biology Platform, Head of Spatial Proteomics

SciLifeLab

Charlotte Stadler is a co-director of the Spatial and single cell Biology (SSCB) platform at Science for Life Laboratory. She is also the Head of the National Spatial Proteomics facility. She received her Ph.D. in 2012 within the framework of the Human Protein Atlas (HPA) project, with Prof. Emma Lundberg and Prof. Mathias Uhlén as her supervisors. During her PhD she established many of the protocols and pipelines for image based subcellular protein profiling that are used in the Human Protein Cell Atlas.

Today, her main focus is to develop and implement services and technologies that can be offered by the Spatial Proteomics Facility. Her internal research projects focus on the implementation of multiplexed imaging solutions into clinical practice but also on integrating different omics types for a more complete molecular understanding of the tissue sample biology.

For more information:

https://www.scilifelab.se/facilities/cell-profiling/

https://www.proteinatlas.org/

Matthew Pugh, MD PhD

Matthew Pugh, MD PhD

MRC Clinical Research Training Fellow

University of Birmingham

October 6th

Live lab demonstrations - breaking down the complexity and work with a sample in, data out approach

October 6th

3:00 PM CEST | 9:00 AM EDT

Speaker

Pedro Almeida, PhD

Pedro Almeida, PhD

Application Development Scientist - Scientific Affairs

Lunaphore

Dr. Pedro Machado Almeida is a molecular biologist by training who obtained his master’s and doctorate degrees from the University of Geneva (Switzerland). Early in his career, he specialized in biomarker studies and worked in a variety of domains, ranging from immuno-oncology to neurodegenerative diseases. He is now the main scientist in charge of scientific collaboration between Lunaphore Technologies and academic partners, where he develops automated high-plex immunoassays.

October 6th

3:30 PM CEST | 9:30 AM EDT

Speaker

Pedro Almeida, PhD

Pedro Almeida, PhD

Application Development Scientist - Scientific Affairs

Lunaphore

Dr. Pedro Machado Almeida is a molecular biologist by training who obtained his master’s and doctorate degrees from the University of Geneva (Switzerland). Early in his career, he specialized in biomarker studies and worked in a variety of domains, ranging from immuno-oncology to neurodegenerative diseases. He is now the main scientist in charge of scientific collaboration between Lunaphore Technologies and academic partners, where he develops automated high-plex immunoassays.

October 6th

4:00 PM CEST | 10:00 AM EDT

The identification of the markers expressed in the tumor microenvironment (TME) and their spatial distribution is key to understanding tumor growth and heterogeneity, as well as to direct therapeutic selection.

In this 30-min webinar, Dr. Ghislaine Lioux will present how the HALO® and HALO AI™ software solutions can be used to analyze images of immuno-oncology panels encompassing a 20-biomarker panel from the COMET™ platform.

During a live demonstration of the HALO and HALO AI software, you will learn:

  • How to intuitively segment the tumoral and stromal compartments with artificial intelligence
  • How to phenotype cells and map their spatial distribution, density, and interactions
  • How to automate the analysis of highly variable samples and overcome artefacts in tissue microarrays

Speaker

Ghislaine Lioux, PhD

Ghislaine Lioux, PhD

Senior Field Applications Scientist

Indica Labs

Ghislaine Lioux has a background in molecular biology and heart development. She was awarded a Marie Curie Fellowship and obtained her PhD from the Spanish National Institute of Cardiovascular Research in Madrid. Ghislaine brings with her 10 years of experience in the immunostaining and imaging world from various institutes in Europe and the USA. As a Sr. Field Application Scientist at Indica Labs, Ghislaine works daily with scientists from Pharmaceutical, Healthcare, and Research Organizations worldwide and provides tailored sales and application support to the customers.

October 7th

High-parameter assay and analysis pipelines

October 7th

3:00 PM CEST | 9:00 AM EDT

Speaker

Francois Rivest, Ph.D.

Francois Rivest, Ph.D.

Team Leader Application Development

Lunaphore

Dr. François Rivest obtained his Ph.D. in Bioengineering and Biotechnology from the Swiss Federal Institute of Technology in Lausanne (EPFL), working on microfluidic technologies, in vitro 3D tumor models, and cancer immunotherapy involving clinical and international collaborations. He is now leading the team of hyperplex panel and reagent development at Lunaphore.

October 7th

3:30 PM CEST | 9:30 AM EDT

  • A guided bi-directional workflow tailored for setting phenotypes with continuous QC and review of results
  • Powerful pre-trained nuclear detection APPs for multiplex immunofluorescence and IMC (imaging mass cytometry).
  • Easy-to-use channel management tools to QC images and review biomarker localization. Group your channels of interest in multiple meaningful 7-color channel groups to quickly toggle between panels.
  • An advanced interactive Data Exploration and QC toolbox including, t-SNE, Scatter and Box-plotting capabilities

Speaker

David Mason, Ph.D.

David Mason, Ph.D.

Senior Technical Specialist

Visiopharm

David Mason is a senior technical specialist in advanced imaging and image analysis. He has an academic background, having been trained in cell biology, Microbiology and Immunology. He currently applies his expertise in multiplex phenotyping and deep learning applications to support the european sales team at Visiopharm.

October 7th

4:00 PM CEST | 10:00 AM EDT

Join this talk to discover more on:

  • Interactive visualization and computational analysis of high-dimensional immunofluorescence slide microscopy imaging data for cancer research and molecular cancer diagnostics
  • Combination of human expert annotation, machine learning-based computer vision, and spatial statistics for quantitative single-cell analysis to describe and model patterns of immune cell infiltrates and interactions between individual cells in spatial tissue context
  • Discovery and development of quantitative tissue imaging biomarkers for molecularly targeted therapy and immunotherapy

Speaker

Markus D. Herrmann, MD, PhD

Markus D. Herrmann, MD, PhD

Assistant Professor of Pathology, Harvard Medical School & Director of Computational Pathology

Massachusetts General Hospital

Register now

The Spatial Biology Week™ 2022

Once you register, you will receive an email with the link to the presentation platform from BigMarker.

"*" indicates required fields

Terms & Conditions*

Related Events